Aligos Therapeutics, Inc.ALGSEarnings & Financial Report
Nasdaq
NextMar 31, 2026
ALGS Q3 2025 Key Financial Metrics
Revenue
$741.0K
Gross Profit
N/A
Operating Profit
$-28.4M
Net Profit
$-31.5M
Gross Margin
N/A
Operating Margin
-3827.4%
Net Margin
-4256.0%
YoY Growth
-40.7%
EPS
$-3.04
Financial Flow
Aligos Therapeutics, Inc. Q3 2025 Financial Summary
Aligos Therapeutics, Inc. reported revenue of $741.0K for Q3 2025, with a net profit of $-31.5M (-4256.0% margin). Cost of goods sold was N/A, operating expenses totaled N/A.
Key Financial Metrics
| Total Revenue | $741.0K |
|---|---|
| Net Profit | $-31.5M |
| Gross Margin | N/A |
| Operating Margin | -3827.4% |
| Report Period | Q3 2025 |
Aligos Therapeutics, Inc. Annual Revenue by Year
Aligos Therapeutics, Inc. annual revenue history includes year-by-year totals (for example, 2024 revenue was $3.6M).
| Year | Annual Revenue |
|---|---|
| 2024 | $3.6M |
| 2023 | $6.2M |
Income Statement
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $672000 | $694000 | $1.1M | $1.3M | $606000 | $311000 | $965000 | $741000 |
| YoY Growth | N/A | 395.7% | -75.3% | 15.2% | -9.8% | -55.2% | -9.0% | -40.7% |
Balance Sheet
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $151.5M | $127.9M | $108.8M | $88.4M | $70.1M | $150.7M | $134.7M | $109.8M |
| Liabilities | $59.4M | $68.1M | $41.6M | $38.3M | $99.1M | $34.3M | $32.8M | $37.9M |
| Equity | $92.1M | $59.8M | $67.2M | $50.1M | $-29.0M | $116.4M | $101.9M | $71.8M |
Cash Flow
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-22.7M | $-22.7M | $-19.5M | $-20.1M | $-18.4M | $-20.9M | $-15.5M | $-24.3M |